The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKrm22 Plc Regulatory News (KRM)

Share Price Information for Krm22 Plc (KRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.50
Bid: 25.00
Ask: 30.00
Change: 2.50 (10.00%)
Spread: 5.00 (20.00%)
Open: 27.50
High: 27.50
Low: 27.40
Prev. Close: 25.00
KRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

12 Jan 2021 07:00

RNS Number : 3137L
KRM22 PLC
12 January 2021
 

KRM22 plc

 

("KRM22", the "Group" or the "Company")

 

Trading update

 

KRM22 plc (AIM: KRM.L) announces a trading update for the 12 month period to 31 December 2020 ("FY2020").

 

The Company continued to make good progress during the year, winning top tier institutions as customers. Increases in new contracted ARR have been offset by churn in its existing customer base as firms inevitably adjusted to the new trading environment as a result of COVID-19.

For FY2020 the Group expects to report:

· A significantly improved adjusted EBITDA loss of approximately £0.1m (FY2019: loss of £3.1m)

· Revenue of approximately £4.6m (FY2019: £4.1m)

· Gross cash as at 31 December 2020 was £2.0m (FY2019: £1.1m)

· ARR at 31 December 2020 of £4.3m (FY2019: £4.3m) at the 2020 constant exchange rate (£4.1m at current rates)

o New contracted ARR in FY2020 of £0.8m, reflecting a gross organic growth rate of 19%

The Company has a near term pipeline of a further £0.5m ARR of deals which are in final contract negotiations and which are expected to be signed in Q1 2021. In addition to this the Company has a strong pipeline of opportunities for 2021. Whilst the net contracted ARR has remained static at £4.3m, the new contracted ARR in FY2020 is made up of higher quality customers. Sterling's continued strengthening against the US dollar has had a negative impact on contracted ARR as described above.

The Board is pleased to note that the Company signed contracts with two, tier one banks in the second half of the year. One of the contracts covered a pre implementation phase for the At Trade Market Risk product, which will lead to significant contracted ARR in 2021. The second contract for £0.2m ARR was signed in December for the Pre Trade Market Risk product.

The total new contracted ARR in FY2020 of £0.8m is spread across different risk domains including £0.5m on Market Risk products, £0.2m on Compliance Risk products and £0.1m on Enterprise Risk products. The new contracted ARR is derived from six new customers, including top tier institutions, and two existing customers. The sale of new risk products to existing customers and the signing of a contract for a suite of products to a UK Brokerage firm, as referred to in the announcement of August 2020, demonstrates KRM22's ability to simplify the cost and complexity of risk management through technology delivered on one platform as a one-stop service.

The total churn in FY2020 for institutional customers was £0.8m which included some legacy customers acquired through previous acquisitions. In addition, a number of our trader customers were lost as they were unable to trade due to the CME floor being closed as a result of the COVID-19 lockdown. The overall level of churn in FY2020 has been significantly higher than we have experienced historically or was expected but management expects this to stabilise in 2021. We settled the disputed contract referred to in previous announcements in December. While in our view our case was strong, we decided that the agreed settlement was pragmatically the right action to avoid the uncertainty, distraction and cost of litigation. The balance has been written off in FY2020.

Costs continue to be under tight control however we have started to phase back the voluntary salary sacrifices in Q4 2020, with phased full reinstatement starting in January 2021 and expected to complete in January 2022.

The Group's net debt as at 31 December 2020 was £1.0m (31 December 2019: £0.9m) and included cash of £2.0m and gross debt, relating to the three-year convertible loan that was signed with Kestrel Partners LLP in September 2020, of £3.0m (31 December 2019: cash of £1.1m and gross debt of £2.0m).

The Company expects to report full year results for the year to 31 December 2020 on 16 March 2021.

 

Keith Todd, Executive Chairman and CEO at KRM22, commented: 'The year has been challenging but we have made good progress in improving the quality of our customer revenue base with increased cross sale opportunities and a significant reduction in our adjusted EBITDA loss. The strengthened balance sheet provides a sound financial base for 2021.

Our Global Risk Platform has matured well and has an increasing positive impact in creating new sales opportunities.

The KRM22 business is in a much stronger position than a year ago and is well placed for growth in 2021.'

 

For further information please contact:

KRM22 plc InvestorRelations@krm22.com

Keith Todd CBE, Executive Chairman and CEO

Kim Suter, CFO

 

finnCap Ltd (Nominated Adviser and Sole Broker) +44 (0)20 7220 0500

Carl Holmes / Kate Bannatyne / Matthew Radley

Alice Lane / Sunila de Silva (ECM)

 

About KRM22 plc

KRM22 is a closed-ended investment company which listed on AIM on 30 April 2018. The Company has been established with the objective of creating value for its investors through the investment in, and subsequent growth and development of, target companies in the technology and software sector, with a focus on risk management in capital markets.

 

Through its investments and the Global Risk Platform, KRM22 helps capital market companies reduce the cost and complexity of risk management. The Global Risk Platform provides applications to help address firms' regulatory, market, technology and operations risk challenges and to manage their entire enterprise risk profile.

 

Capital markets companies' partner with KRM22 to optimise risk management systems and processes, improving profitability and expanding opportunities to increase portfolio returns by leveraging risk as alpha.

 

KRM22 plc is listed on AIM and the Group is headquartered in London, with offices in several of the world's major financial centres.

 

See more about KRM22 at KRM22.com.

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFFFAFEFSEDF
Date   Source Headline
16th Apr 20247:00 amRNSDirector Dealings
15th Apr 20247:00 amRNSNew Customer Contract
10th Apr 20247:00 amRNSIssue of Equity
7th Mar 20247:00 amRNSBoard Changes
21st Feb 20247:00 amRNSTrading Update
1st Dec 20237:00 amRNSIssue of Restricted Stock Units
26th Sep 20237:00 amRNSInterim Results
27th Jul 202311:48 amRNSResult of General Meeting
21st Jul 20237:00 amRNSDirector Dealing
20th Jul 20237:00 amRNSHalf Year Trading Update
4th Jul 20237:00 amRNSPosting of Accounts, Circular and Notice of GM
30th Jun 202312:41 pmRNSResult of AGM
27th Jun 20237:00 amRNSFinal Results
19th Jun 20237:00 amRNSNew Debt Facility
8th Jun 20237:00 amRNSAnnual Report and Notice of AGM
16th Dec 20223:15 pmRNSIssue of Options
20th Sep 20227:00 amRNSInterim Results
13th Jun 202210:00 amRNSHolding(s) in Company
5th May 202212:00 pmRNSResult of AGM
20th Apr 20222:30 pmRNSDirector Dealing
12th Apr 20227:00 amRNSNotice of AGM and Posting of Annual Report
7th Apr 20224:30 pmRNSHolding(s) in Company
28th Mar 20225:30 pmRNSHolding(s) in Company
23rd Mar 20227:00 amRNSFinal Results
15th Mar 20227:00 amRNSProduct Launch Under Distribution Agreement
1st Mar 20227:00 amRNSUpdate re Annual Results (Change of Date)
31st Jan 20227:00 amRNSTrading Update
5th Jan 202210:47 amRNSHolding(s) in Company
30th Dec 20219:47 amRNSSubscription Completion, Executive Changes and TVR
22nd Dec 20217:00 amRNSSubscription Update
22nd Nov 20217:00 amRNSHolding(s) in Company
1st Nov 20217:00 amRNSSubscription Agreement and Trading Update
20th Oct 20213:43 pmRNSHolding(s) in Company
16th Sep 20212:38 pmRNSDirector/PDMR Shareholding
13th Sep 20219:52 amRNSDirector/PDMR Shareholding
10th Sep 20212:48 pmRNSDirector/PDMR Shareholding
8th Sep 202112:00 pmRNSDirector/PDMR Shareholding
2nd Sep 20217:00 amRNSDirector/PDMR Shareholding
1st Sep 20217:00 amRNSInterim Results
30th Jul 20217:00 amRNSContract Extension
22nd Jul 20217:00 amRNSHalf Year Trading Update
24th Jun 20217:00 amRNSKRM22 announces partnership with Waymark Tech
28th Apr 20211:29 pmRNSResult of AGM
19th Apr 20217:00 amRNSExercise of options and total voting rights
26th Mar 20213:24 pmRNSHolding(s) in Company
23rd Mar 20218:00 amRNSNotice of AGM and Posting of Annual Report
18th Mar 20215:39 pmRNSHolding(s) in Company
16th Mar 202111:06 amRNSTechnology Demonstration
16th Mar 20217:00 amRNSFinal Results
24th Feb 20217:00 amRNSKRM22 announces new partnership

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.